Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia.
Maria Paz Garcia-PortillaPierre Michel LlorcaGiuseppe MainaVasilis P BozikasHalise Devrimci-OzguvenSung-Wan KimPaul BergmansIrina UsankovaKatalin PungorPublished in: Therapeutic advances in psychopharmacology (2020)
Results from this naturalistic study were similar to those observed in previous randomized clinical trials of PP3M and underline the importance of continuous maintenance treatment in patients with schizophrenia.